Mycobacterium tuberculosis ESAT6 CFP10 antigen - AnHui Longcom Biologic Pharmacy

Drug Profile

Mycobacterium tuberculosis ESAT6 CFP10 antigen - AnHui Longcom Biologic Pharmacy

Alternative Names: ESAT6-CFP10; Mycobacterium riyadhense vaccine - AnHui Longcom Biologic Pharmacy; Recombinant EC allergen; TB-PPD

Latest Information Update: 03 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AnHui Longcom Biologic Pharmacy
  • Class Antibody diagnostics; Immunotherapies; Tuberculosis vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Tuberculosis

Most Recent Events

  • 03 Feb 2017 Anhui Zhifei Longcom Biopharmaceutical plans a phase I trial for Tuberculosis (prevention) in China (NCT03026972)
  • 01 Oct 2016 Phase-III clinical trials in Tuberculosis (Diagnosis, In adolescents, In children, In infants, In neonates) in China (Intradermal) (NCT03027154)
  • 01 Oct 2016 Anhui Zhifei Longcom Biopharmaceutical and Jiangsu Provincial Center for Disease Control and prevention completes a phase III trial for Tuberculosis (Diagnosis) in China (Intradermal) (NCT02795260; ChiCTR-IIR-16007904)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top